Merck KGaA (MKKGY) Stock Price & Analysis
Merck KGaA (MKKGY) — price $30.87 (+2.52%), as of the Oct 2, 2026 trading session; market cap $67.1B. Expected results Nov 12, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Merck KGaA · MKKGY · Healthcare · Drug Manufacturers - Specialty & Generic
Merck KGaA is a leading German science and technology enterprise. Its business operations are strategically organized into three core divisions: Life Science, Healthcare, and Electronics.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $30.87 | |
| Change on the day | +2.52% | |
| 52-week range | $23.73 – $34.19 | |
| Market capitalisation | $67.1B | |
| Price / earnings (trailing) | 25.12 | |
| Shares traded on the day | 5.7K | |
| Beta (volatility vs the S&P 500) | 0.81 | |
| Dividends per share (last 12 months) | $0.51 | |
| Dividend yield (last 12 months) | 1.67% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
But again, I want to remind us to mind the capacity constraints of our customers, especially in the AI segment, which are already happening today and which we believe will extend well into the next year as well as we debottleneck as an industry.
Benjamin Hein · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Merck KGaA (MKKGY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the MKKGY film — every key number, told as a short cinematic story
~2 min · open the film
What is Merck KGaA (MKKGY), and what does it report?
Short answer · as of
Life Science sells tools, chemicals, equipment, testing products, and process expertise to researchers, biotechnology companies, drug manufacturers, and industrial customers.
Research dated 2026-09-12.
Life Science sells tools, chemicals, equipment, testing products, and process expertise to researchers, biotechnology companies, drug manufacturers, and industrial customers. Healthcare develops and commercializes medicines across oncology, neurology, immunology, fertility, endocrinology, and other therapeutic areas, while Electronics supplies semiconductor and display materials alongside delivery systems and surface products.
What do the latest results show for Merck KGaA (MKKGY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $6.18B. Against analyst estimates the company has EPS beat 6 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $6.27B Aug 6, 2026
- Latest report · revenue estimate
- $6.08B Aug 6, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 6, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | $6.27B | $6.08B | $0.2600 | $0.4700 |
| May 13, 2026 | $6.01B | $5.93B | $0.5900 | $0.4500 |
| Mar 5, 2026 | $6.08B | $6.20B | $0.2800 | $0.4700 |
| Nov 13, 2025 | $6.17B | $6.08B | $0.8100 | $0.5400 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $6.18B | $557M | $0.26 (diluted) |
| Q1 FY2026 | $5.74B | $737M | $0.34 (diluted) |
| Q4 FY2025 | $5.82B | $353M | $0.16 (diluted) |
| Q3 FY2025 | $5.95B | $1.01B | $0.46 (diluted) |
What are the financial strengths and risks for Merck KGaA (MKKGY)?
Short answer
The distress and quality screens read Altman Z 3.05 · Piotroski F 6. Trailing ratios: ROE 8.1% · ROA 4.5% · current ratio 1.69 · earnings yield 3.9% · free-cash-flow yield 4.4%.
What should you watch next at Merck KGaA (MKKGY)?
Short answer · as of
The next earnings report is expected on Nov 12, 2026.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
But again, I want to remind us to mind the capacity constraints of our customers, especially in the AI segment, which are already happening today and which we believe will extend well into the next year as well as we debottleneck as an industry.
Benjamin Hein ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
What has been published about Merck KGaA (MKKGY)?
What Investors Ask About Merck KGaA (MKKGY) — Healthcare
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Merck KGaA more than a pharmaceutical manufacturer?
Prescription medicines sit alongside Life Science tools and bioprocessing expertise, plus Electronics materials used in semiconductor, display, and surface applications. Consolidated results therefore reflect laboratory activity and electronics production as well as medicine demand.
How can semiconductor customer bottlenecks affect Merck KGaA?
Merck KGaA supplies materials and delivery systems used by semiconductor customers, so constrained customer capacity can postpone material consumption and limit near-term sales conversion. Management expects those constraints to persist while the industry removes bottlenecks.
What is the MKKGY stock price today?
The last price recorded on this page for Merck KGaA (MKKGY) is $30.87, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does MKKGY pay a dividend?
Yes. Merck KGaA (MKKGY) shows a trailing 12-month dividend yield of 1.67%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (40 figures)
The 40 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Benjamin Hein (Aug 6, 2026): But again, I want to remind us to mind the capacity constraints of our customers, especially in the AI segment, which are already happening today and which we believe will extend well into the next year as well as we debottleneck as an industry. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 30 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $30.87 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T19:24:41.808Z. | |
px.change | Change on the day | +2.52% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $67.1B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T19:24:40.734Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 12, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Merck KGaA is a leading German science and technology enterprise. Its business operations are strategically organized into three core divisions: Life Science, Healthcare, and Electronics. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.76 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 25.12 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5.7K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.81 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Kai Beckmann | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 62,461 | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Frankfurter Strasse 250, Darmstadt, HE, 64293, DE | FMP | Financial Modeling Prep (FMP) company profile | |
fin.q_revenue | Revenue, Q2 FY2026 | $6.18B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-06.revenue_actual | Revenue · reported — report date 2026-08-06 | $6.27B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.revenue_estimated | Revenue · estimate — report date 2026-08-06 | $6.08B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | $0.2600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | $0.4700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.revenue_actual | Revenue · reported — report date 2026-05-13 | $6.01B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.revenue_estimated | Revenue · estimate — report date 2026-05-13 | $5.93B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.eps_actual | EPS · reported — report date 2026-05-13 | $0.5900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.eps_estimated | EPS · estimate — report date 2026-05-13 | $0.4500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.revenue_actual | Revenue · reported — report date 2026-03-05 | $6.08B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.revenue_estimated | Revenue · estimate — report date 2026-03-05 | $6.20B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.eps_actual | EPS · reported — report date 2026-03-05 | $0.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.eps_estimated | EPS · estimate — report date 2026-03-05 | $0.4700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-13.revenue_actual | Revenue · reported — report date 2025-11-13 | $6.17B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-13.revenue_estimated | Revenue · estimate — report date 2025-11-13 | $6.08B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-13.eps_actual | EPS · reported — report date 2025-11-13 | $0.8100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-13.eps_estimated | EPS · estimate — report date 2025-11-13 | $0.5400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $23.73 – $34.19 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-19 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.05 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 8.1% · ROA 4.5% · current ratio 1.69 · earnings yield 3.9% · free-cash-flow yield 4.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.51 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 1.67% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-06.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($6.27B) with the recorded estimate ($6.08B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.2600) with the recorded estimate ($0.4700) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.revenue_actual,earn.history.depth.2026-08-06.revenue_estimated,earn.history.depth.2026-08-06.revenue_actual.comparison,earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-13.revenue_actual,earn.history.depth.2026-05-13.revenue_estimated,earn.history.depth.2026-05-13.eps_actual,earn.history.depth.2026-05-13.eps_estimated,earn.history.depth.2026-03-05.revenue_actual,earn.history.depth.2026-03-05.revenue_estimated,earn.history.depth.2026-03-05.eps_actual,earn.history.depth.2026-03-05.eps_estimated,earn.history.depth.2025-11-13.revenue_actual,earn.history.depth.2025-11-13.revenue_estimated,earn.history.depth.2025-11-13.eps_actual,earn.history.depth.2025-11-13.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Merck KGaA is a leading German science and technology enterprise. Its business operations are strategically organized into three core divisions: Life Science, Healthcare, and Electronics. The Life Science segment provides an extensive portfolio of tools, chemicals, and equipment essential for academic research laboratories, biotech firms, pharmaceutical manufacturers, and the broader industrial sector. This division also furnishes drug developers with specialized process development expertise and advanced technologies, such as continuous bioprocessing, alongside a variety of testing kits, reagents, and associated services. Furthermore, it delivers analytical solutions for environmental monitoring (air, water, and soil) and products designed to evaluate nutritional content and detect quality deviations. The Healthcare segment focuses on the discovery, development, manufacturing, and commercialization of prescription drugs and biopharmaceuticals. Its therapeutic areas encompass oncology, neurology and immunology, fertility, endocrinology, cardiovascular conditions, diabetes, thyroid disorders, and multiple sclerosis. This segment also markets general medicines and integrates medical technology, including injection devices and disease monitoring software. The Electronics segment supplies critical materials to the semiconductor and display industries. It also specializes in surface design solutions, offering comprehensive delivery systems, services, and innovative surface products, which include cosmetic ingredients, effect pigments, and various functional applications. Beyond its internal operations, Merck KGaA actively pursues strategic collaborations. This includes in-licensing agreements, such as with Debiopharm International SA for drug candidates targeting head and neck cancer; with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for treatments against metastatic colorectal cancer; and with Abbisko Therapeutics Co. Ltd. for therapies for tenosynovial giant cell tumor. The company also holds a license and collaboration agreement dedicated to identifying two targeted protein degraders for vital oncogenic proteins. Established in 1668, Merck KGaA boasts a long and distinguished history and is headquartered in Darmstadt, Germany. The company functions as a subsidiary under the umbrella of E. Merck KG. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - Specialty & Generic | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Management outlook — dated call excerpts | Captured record · 1 entry
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-06 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
Data provided for informational purposes only.